|
Oct 16
|
Is Sarepta Therapeutics, Inc. (SRPT) the Most Promising Biotech Stock According to Hedge Funds?
|
|
Sep 8
|
Sarepta Therapeutics, Inc. (SRPT): This Biotech Stock Should Be On Your Radar
|
|
Sep 6
|
Why Is Sarepta Therapeutics (SRPT) Down 1.9% Since Last Earnings Report?
|
|
Sep 5
|
Sarepta Therapeutics Announces Recipients of the 7th Annual Route 79, The Duchenne Scholarship Program, for the 2024-2025 Academic Year
|
|
Aug 1
|
Sarepta Therapeutics (NASDAQ:SRPT) A Bull Case Theory
|
|
Jul 30
|
Zacks Industry Outlook Highlights Moderna, Sarepta Therapeutics, Halozyme Therapeutics, Krystal Biotech and Axsome Therapeutics
|
|
Jul 29
|
Sarepta Therapeutics Poised for 'Significant Launch Inflection' Amid Positive Elevidys Feedback, RBC Says
|
|
Jul 29
|
5 Biotech Stocks to Bet On Bright Industry Prospects
|
|
Jul 29
|
Sarepta Therapeutics to Announce Second Quarter 2024 Financial Results
|
|
Jun 27
|
Biotech Stock Roundup: ALNY Up on Study Success, ALIM on Merger News & Other Updates
|
|
Jun 26
|
Is Pfizer's Pain Sarepta Therapeutics' Gain? Don't Bet on It.
|
|
Jun 26
|
Insider Sale: EVP, General Counsel Ryan Brown Sells 38,957 Shares of Sarepta Therapeutics Inc (SRPT)
|
|
Jun 24
|
Sarepta Therapeutics Scores 90-Plus RS Rating On Muscular Dystrophy Approval
|
|
Jun 24
|
Company News for Jun 24, 2024
|
|
Jun 24
|
Sarepta Therapeutics (SRPT) Soars 30.1%: Is Further Upside Left in the Stock?
|
|
Jun 21
|
What next for gas prices, how the S&P 500 can reach 6,000: Market Domination
|
|
Jun 21
|
Sarepta Catapults 30% After Hitting A 'Grand Slam' Approval In Muscular Dystrophy
|
|
Jun 21
|
These Stocks Moved the Most Today: Nvidia, Microsoft, Trump Media, Sarepta, Palantir, Hertz, Smith & Wesson, and More
|
|
Jun 21
|
Sector Update: Health Care Stocks Gain in Late Afternoon
|
|
Jun 21
|
Sarepta's Stock Soars on Best-Case FDA Decision for its Muscular Dystrophy Treatment
|